Renal cell carcinoma (RCC) represents 2-3% of adult malignant tumors and constitutes 90% of the malignant tumors that affect the kidney. RCC metastatic disease (m-RCC) occurs in a significant percentage and is usually associated with an overall poor prognosis. This tumor is hypervascular and that is why tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the vascular endothelial growth factor receptor, have become established as the most successful drug in this

more »

... se. These drugs interfere in the angiogenesis of the RCC, thus modifying the radiological image by CT with contrast, making them necessary to study the evolution of the radiological aspect of the findings. Because of mechanism of action of TKI is complex and its effect is different according to the organ in which they act, a heterogeneous radiological response of the metastatic lesions can be expected. Knowledge of this different behavior depending on the organ is mandatory to correctly evaluate the response to treatment.